explore -WSS

explore

author：explore 2025-09-03 14:39:39 - browse：1463

Each COVID-19 vaccine vial from various companies is placed on individual rectangular backgrounds. Pfizer-BioNTech is positioned in the middle on a purple block adorned with two glitter star stickers, Moderna is on the top right on a red block, Janssen is on the bottom right on a blue block, and AstraZeneca is on the left on a red block. — Illustration: Christine Kao/STAT; Photos: Getty

It’s been four years since Covid-19 emerged, igniting a pandemic that killed millions of people and brought the world to its knees. A key factor in taming the pandemic was the creation of effective vaccines, which have saved millions of lives.

You’d think developing a successful vaccine would be an unmitigated win, from a financial perspective. And, indeed, for Pfizer and its partner BioNTech, as well as for Moderna — whose vaccines were the most widely used in the United States and much of the world — the revenues generated were absolutely staggering. But investors have shrugged at those sales as gains that will not be repeated.

Total sales of the Pfizer/BioNTech vaccine surpassed $80 billion, and more than 400 million doses of the shot and subsequent boosters have been administered in the U.S. alone. But the company’s stock price fell 32% over the past five years. Meanwhile, AstraZeneca, which told STAT it has not booked sales from its vaccine since last April and does not expect future sales, has seen its share price rise 64%. Merck, which saw its vaccine efforts fail twice, is up 56%.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Orchard's therapy for neuron disease in children wins FDA approval

knowledge

WSS

Judge rejects Trump's request to move Stormy Daniels hush

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Nurses recount patients attacks

Divers poised to search for children washed away in Pennsylvania flash flood

Affordable Connectivity Program vital to health care, experts say

Intermittent fasting comes with a heart risk? Not so fast

focus

explore

leisure time

Medicare details structure of new drug price negotiation program

Awakening the world to the whoosh: A patient's crusade

Walensky prepares to leave CDC — and Congress — behind

Future doctors should be trained to promote social change

The cancer drug shortage isn’t new — and neither are the solutions

UnitedHealth increases loan offers after Change Healthcare outage

Tori Bowie and the unacceptable rates of Black maternal death

Mass General totes up its waste in a move to tackle climate change

Wildfire smoke exposes gaps in outdoor worker protections

App could help diagnose ear infections more accurately — and at home

knowledge

Stanford president's case begs question: Who takes blame?

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

DeSantis talks Trump, trans issues and 'what wokeness is'

App could help diagnose ear infections more accurately — and at home

Mass General totes up its waste in a move to tackle climate change

Stop the failed accountable care organization experiment

leisure time

knowledge

knowledge

hotspot